ArticleJournal of medicinal chemistry2026
First Structure-Activity-Relationship Study of Potent G2A Antagonists.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
G2A inhibition has recently been proposed as a novel therapeutic approach to treat oxaliplatin-induced neuropathic pain (OINP) and breast cancer. However, very few G2A antagonists are known to date. In this study, we report the discovery of a novel series of G2A antagonists developed within our research group, along with the first comprehensive structure-activity relationship (SAR) investigation for this class of compounds. Utilizing a rational design approach, we systematically explored the effects of structural modifications on G2A receptor binding and functional activity. The SAR study identified key molecular features critical for potent G2A inhibition. Two of the newly discovered compounds exhibited submicromolar activity and acceptable selectivity profile among GPCRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.